Advertisement
ResearchIn-Press PreviewTherapeutics
Open Access | 10.1172/JCI154152
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Hickman, A. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Koetsier, J. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Kurtanich, T.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Nielsen, M. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Winn, G. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Wang, Y.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Bentebibel, S. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Shi, L. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Punt, S. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Williams, L. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Haymaker, C.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Chesson, C. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Fa'ak, F.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Dominguez, A. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Jones, R. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Kuiatse, I. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Caivano, A. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Khounlo, S. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Warier, N. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Marathi, U. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Market, R. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Biediger, R. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Craft Jr, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Hwu, P. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Davies, M.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Woodside, D.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Vanderslice, P.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Diab, A. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Overwijk, W. in: JCI | PubMed | Google Scholar
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America
2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
3Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, United States of America
4LLC, 7Hills Pharma, Houston, United States of America
5Department of Biology and Chemistry, University of Houston, Houston, United States of America
6The University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Hailemichael, Y.
in:
JCI
|
PubMed
|
Google Scholar
|
Published May 12, 2022 - More info
The inability of CD8+ T effectors (Teff) to reach tumor cells is an important mechanism of tumor resistance to cancer immunotherapy. The recruitment of these cells to the tumor microenvironment (TME) is regulated by integrins, a family of adhesion molecules that is expressed on T cells. Here we show that 7HP349, a small molecule activator of Lymphocyte function–associated antigen-1 (LFA-1) and very late activation antigen-4 (VLA-4) integrin-cell-adhesion receptors, facilitated the preferential localization of tumor-specific T cells to the tumor and improve antitumor response. 7HP349 monotherapy had modest effects on anti- programmed death 1 (PD-1)–resistant tumors, whereas combinatorial treatment with anti- T-lymphocyte-associated protein 4 (CTLA-4) therapy increased CD8+ Teff intratumoral sequestration and synergized in inducing cancer regression, in cooperation with neutrophils. 7HP349 intratumoral CD8+ Teff enrichment activity depended on CXCL12. We analyzed gene expression profiles using RNA from baseline and on treatment tumor samples of 14 melanoma patients. We identified baseline CXCL12 gene expression may improve response likelihood to anti-CTLA-4 therapies. Our results provided a proof-of-principle demonstration that LFA-1 activation could convert a T cell-exclusionary TME to a T-cell enriched TME through mechanisms involving cooperation with innate immune cells.